A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
Condition: Carcinoma, Squamous Cell Interventions: Drug: A317; Drug: VTX-2337 Sponsor: Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials